JP2014507450A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014507450A5 JP2014507450A5 JP2013557032A JP2013557032A JP2014507450A5 JP 2014507450 A5 JP2014507450 A5 JP 2014507450A5 JP 2013557032 A JP2013557032 A JP 2013557032A JP 2013557032 A JP2013557032 A JP 2013557032A JP 2014507450 A5 JP2014507450 A5 JP 2014507450A5
- Authority
- JP
- Japan
- Prior art keywords
- lta
- infections
- pharmaceutical composition
- mimetic
- molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 239000002253 acid Substances 0.000 claims 7
- 102000004965 antibodies Human genes 0.000 claims 4
- 108090001123 antibodies Proteins 0.000 claims 4
- 229960005486 vaccines Drugs 0.000 claims 3
- 206010003997 Bacteraemia Diseases 0.000 claims 2
- 241000894006 Bacteria Species 0.000 claims 2
- 208000009361 Bacterial Endocarditis Diseases 0.000 claims 2
- 206010060945 Bacterial infection Diseases 0.000 claims 2
- 206010014666 Endocarditis bacterial Diseases 0.000 claims 2
- 206010014889 Enterococcal infection Diseases 0.000 claims 2
- 206010034674 Peritonitis Diseases 0.000 claims 2
- 206010035664 Pneumonia Diseases 0.000 claims 2
- 206010062255 Soft tissue infection Diseases 0.000 claims 2
- 241000295644 Staphylococcaceae Species 0.000 claims 2
- 206010046577 Urinary tract infection Diseases 0.000 claims 2
- 206010048038 Wound infection Diseases 0.000 claims 2
- 150000001720 carbohydrates Chemical group 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 201000009906 meningitis Diseases 0.000 claims 2
- 230000001225 therapeutic Effects 0.000 claims 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims 1
- 102000014914 Carrier Proteins Human genes 0.000 claims 1
- 108010078791 Carrier Proteins Proteins 0.000 claims 1
- 241000193163 Clostridioides difficile Species 0.000 claims 1
- GZCGUPFRVQAUEE-KCDKBNATSA-N D-(+)-Galactose Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-KCDKBNATSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 241000194031 Enterococcus faecium Species 0.000 claims 1
- 241000192125 Firmicutes Species 0.000 claims 1
- 229960003082 Galactose Drugs 0.000 claims 1
- DLRVVLDZNNYCBX-LIZSDCNHSA-N Gentiobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1 DLRVVLDZNNYCBX-LIZSDCNHSA-N 0.000 claims 1
- 229960002442 Glucosamine Drugs 0.000 claims 1
- PZDOWFGHCNHPQD-OQPGPFOOSA-N Kojibiose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](C=O)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O PZDOWFGHCNHPQD-OQPGPFOOSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-Acetylglucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims 1
- 229950006780 N-Acetylglucosamine Drugs 0.000 claims 1
- 206010034133 Pathogen resistance Diseases 0.000 claims 1
- PNNNRSAQSRJVSB-BXKVDMCESA-N Rhamnose Chemical compound C[C@H](O)[C@H](O)[C@@H](O)[C@@H](O)C=O PNNNRSAQSRJVSB-BXKVDMCESA-N 0.000 claims 1
- 241000191967 Staphylococcus aureus Species 0.000 claims 1
- 229940076185 Staphylococcus aureus Drugs 0.000 claims 1
- 241000194017 Streptococcus Species 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000000240 adjuvant Effects 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 125000000600 disaccharide group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 125000005647 linker group Chemical group 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 230000003278 mimic Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 150000002772 monosaccharides Chemical group 0.000 claims 1
- 230000003449 preventive Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 239000007790 solid phase Substances 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000002194 synthesizing Effects 0.000 claims 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N α-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims 1
Claims (15)
- 前記糖質部分が、グルコース(Glu)、グルコサミン、N−アセチルグルコサミン、ガラクトース、ラムノース、ゲンチオビオース、又はコージビオースによって代表される単糖ユニット又は二糖ユニットから選択されるグルコシル部分(Glc)である、請求項1又は2に記載の合成リポテイコ酸(LTA)模倣物。
- nが6であり、zが5である、請求項1〜6のいずれか一項に記載の合成リポテイコ酸(LTA)模倣物。
- 請求項1〜7のいずれか一項に記載のLTA模倣物と、薬学的に許容可能な担体、アジュバント、及び/又は希釈剤とを含む、医薬組成物。
- 前記組成物がワクチンである、請求項8に記載の医薬組成物。
- 少なくとも1種のサイトカインを更に含む、請求項8又は9に記載の医薬組成物。
- 前記ワクチンが、筋肉内経路、皮下経路、又は吸入経路を介する投与のために配合される、請求項8〜10のいずれか一項に記載の医薬組成物。
- 細菌感染症、腸球菌感染症、尿路感染症、菌血症、細菌性心内膜炎、腹膜炎、創傷感染症及び軟部組織感染症、並びに髄膜炎又は肺炎で代表されるグラム陽性細菌によって引き起こされる疾患又は病態の予防的治療又は治療的治療のための請求項1〜11のいずれか一項に記載のLTA分子又は医薬組成物であって、前記グラム陽性細菌がエンテロコッカス・フェシウム、大便連鎖球菌、黄色ブドウ球菌、コアグラーゼ陰性ブドウ球菌、又は化膿性連鎖球菌、肺炎球菌、クロストリジウム・ディフィシルで代表される腸球菌、ブドウ球菌、又は連鎖球菌、及びこれらの抗生物質耐性株から選択される前記LTA分子又は医薬組成物。
- 前記分子を固相材料上に合成することを含む、請求項1〜7のいずれか一項に記載のLTA分子を作製する方法。
- 請求項1〜7のいずれか一項に記載のLTA分子に特異的に結合する抗体を作製する方法であって、請求項1〜7のいずれか一項に記載のLTA分子で好適な動物を免疫することと、前記抗体を前記動物から単離することとを含む、方法。
- 細菌感染症、腸球菌感染症、尿路感染症、菌血症、細菌性心内膜炎、腹膜炎、創傷感染症及び軟部組織感染症、並びに髄膜炎又は肺炎で代表される細菌によって引き起こされる疾患又は病態の予防的治療又は治療的治療のための請求項1〜11のいずれか一項に記載のLTA分子若しくは医薬組成物、又は請求項14の記載の方法に従って作製される抗体であって、前記薬剤がワクチンである、LTA分子若しくは医薬組成物、又は抗体。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161451304P | 2011-03-10 | 2011-03-10 | |
US61/451,304 | 2011-03-10 | ||
EP20110157947 EP2500349B1 (en) | 2011-03-11 | 2011-03-11 | Synthetic LTA mimetics and use thereof as vaccine component for therapy and/or prophylaxis against gram-positive infections |
EP11157947.0 | 2011-03-11 | ||
PCT/EP2012/052801 WO2012119846A1 (en) | 2011-03-10 | 2012-02-17 | Synthetic lta mimetics and use thereof as vaccine component for therapy and/or pro-phylaxis against gram-positive infections |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2014507450A JP2014507450A (ja) | 2014-03-27 |
JP2014507450A5 true JP2014507450A5 (ja) | 2015-03-12 |
JP6154751B2 JP6154751B2 (ja) | 2017-06-28 |
Family
ID=43828266
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013557032A Expired - Fee Related JP6154751B2 (ja) | 2011-03-10 | 2012-02-17 | 合成lta模倣物、並びにグラム陽性感染症の治療及び/又は予防のためのワクチン成分としてのその使用 |
Country Status (7)
Country | Link |
---|---|
US (1) | US9290531B2 (ja) |
EP (1) | EP2500349B1 (ja) |
JP (1) | JP6154751B2 (ja) |
CA (1) | CA2829126A1 (ja) |
ES (1) | ES2544808T3 (ja) |
HK (1) | HK1175786A1 (ja) |
WO (1) | WO2012119846A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10364298B2 (en) | 2011-11-18 | 2019-07-30 | National Research Council Of Canada | Clostridium difficile lipoteichoic acid and uses thereof |
US10781175B2 (en) | 2016-07-15 | 2020-09-22 | Am Chemicals Llc | Solid supports and phosphoramidite building blocks for oligonucleotide conjugates |
KR101950881B1 (ko) * | 2017-08-10 | 2019-02-22 | 서울대학교산학협력단 | 리포테이코익산(Lipoteichoic acid(LTA))을 함유하는 피부 재생 및 창상 치유용 약학 조성물 |
CN116898959A (zh) * | 2017-09-07 | 2023-10-20 | 默沙东有限责任公司 | 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0807185T3 (da) * | 1995-01-30 | 2002-10-07 | Lunamed Ag | Antitumorpræparater indeholdende en lipoteichoinsyre fra streptococcus |
AUPQ137699A0 (en) | 1999-07-02 | 1999-07-22 | University Of New England, The | Control of acidosis |
WO2003066649A1 (en) * | 2002-02-04 | 2003-08-14 | Biomira Inc. | Immunostimulatory, covalently lipidated oligonucleotides |
-
2011
- 2011-03-11 ES ES11157947.0T patent/ES2544808T3/es active Active
- 2011-03-11 EP EP20110157947 patent/EP2500349B1/en not_active Not-in-force
-
2012
- 2012-02-17 CA CA2829126A patent/CA2829126A1/en not_active Abandoned
- 2012-02-17 JP JP2013557032A patent/JP6154751B2/ja not_active Expired - Fee Related
- 2012-02-17 WO PCT/EP2012/052801 patent/WO2012119846A1/en active Application Filing
- 2012-02-17 US US14/002,459 patent/US9290531B2/en not_active Expired - Fee Related
-
2013
- 2013-03-12 HK HK13103062.2A patent/HK1175786A1/xx not_active IP Right Cessation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Amyes | Enterococci and streptococci | |
US20180369262A1 (en) | Methods for treating resistant diseases using triazole containing macrolides | |
Theilacker et al. | Serodiversity of opsonic antibodies against Enterococcus faecalis—glycans of the cell wall revisited | |
JP2014507450A5 (ja) | ||
Zhao et al. | Epidemiology of Haemophilus parasuis isolates from pigs in China using serotyping, antimicrobial susceptibility, biofilm formation and ERIC-PCR genotyping | |
Ghosh et al. | Synthesis of an aminooxy derivative of the tetrasaccharide repeating unit of streptococcus dysgalactiae 2023 polysaccharide for a PS A1 conjugate vaccine | |
JP6154751B2 (ja) | 合成lta模倣物、並びにグラム陽性感染症の治療及び/又は予防のためのワクチン成分としてのその使用 | |
JP6230991B2 (ja) | エンテロコッカス・フェシウムクローナルコンプレックス17に由来するラムノ多糖及びその使用 | |
JP5746217B2 (ja) | 腸球菌の細胞壁成分及びその抗菌的使用 | |
Lonks | What is the clinical impact of macrolide resistance? | |
WO2012105562A1 (ja) | 新規マクロライド誘導体 | |
JP2017537941A5 (ja) | ||
Ball | The future role and importance of macrolides | |
Paukner et al. | Antibacterial in vitro activity of novel extended spectrum pleuromutilins against Gram-positive and-negative bacterial pathogens | |
EP2450053B1 (en) | Novel antigen of enterococcal pathogens and use thereof as vaccine component for therapy and/or prophylaxis | |
Adam | Clinical use of the new macrolides, azalides, and streptogramins in pediatrics | |
WO2012105563A1 (ja) | マクロライド誘導体からなる動物用医薬品 | |
Paukner et al. | Accumulation of the pleuromutilin antibiotic BC-3781 in murine macrophages and effect of lung surfactant on the BC-3781 in vitro activity | |
Paukner et al. | In vitro activity of lefamulin against bacterial pathogens causing community-acquired bacterial pneumonia: SENTRY surveillance 2017–2018 results from the United States [abstract no 703 plus poster] | |
Tran | Telithromycin: a novel agent for the treatment of community-acquired upper respiratory infections | |
Krisztina et al. | A Pasteurella multocida törzsek antibiotikumérzékenysége, az antimikrobiális rezisztencia genetikai háttere Irodalmi összefoglaló. | |
Vansarla | Role of HAMLET and metabolism in treatment and pathogenesis of pneumococci | |
Gronthoud | Invasive Group A Streptococcal Infections | |
JP6226948B2 (ja) | エンテロコッカス・フェカリスの細胞壁高分子及びその使用 | |
Adama et al. | Antibiotic Treatment for Streptococcal Pharyngitis |